// App-Quantinova.ai

284 : Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain Allows Earlier Detection and More Accurate Characterization of Resistant Subclones in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Receiving Tyrosine Kinase Inhibitor-Based Therapies

Researchers

Presenter

  • Caterina De Benedittis

Principal Investigators

  • Katerina Machova Polakova

  • Federica Cattina

  • Robin Foa

  • Antonella Vitale

  • Domenico Russo

  • Michele Baccarani

  • Giovanni Martinelli

  • Adela Brouckova

  • Cristina Papayannidis

  • Paola Bresciani

  • Valeria Coluccio

  • Ilaria Iacobucci

  • Claudia Venturi

  • Mario Luppi

  • Emanuela Ottaviani

Medical Centers

  • Hematology, University of Brescia, Brescia, Italy

  • Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Rome, Italy

  • Department of Hematology/Oncology, University of Bologna, Bologna, Italy

  • Institute of Hematology and Blood Transfusion, Prague, Czech Republic

  • Bone Marrow Transplant Unit, Department of Oncology and Hematology, University of Modena, Modena, Italy

  • Division of Hematology, Department of Hematology and Cellular Biotechnologies, Sapienza University, Roma, Italy

Locations

  • Czech Republic

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Bosutinib

  • Nilotinib

  • Ponatinib

  • dasatinib

  • Imatinib

  • IkT001

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved